Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:

Area of Science:

• Physiology
• Pharmacology
• Urology

Background:

• Penile erection involves nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) signaling pathways.
• Phosphodiesterase type 5 (PDE type 5) regulates cGMP levels in erectile tissue.
• Dysfunctional erectile responses are linked to impaired NO signaling or excessive smooth muscle contraction.

Purpose of the Study:

• To review the physiology of penile erection.
• To discuss the pharmacology, metabolism, and clinical use of sildenafil citrate.
• To highlight sildenafil's role in managing erectile dysfunction.

Main Methods:

• Literature review of physiological mechanisms.
• Pharmacological analysis of PDE type 5 inhibition.
• Summary of clinical data on sildenafil efficacy.

Main Results:

• Sildenafil citrate selectively inhibits PDE type 5, preventing cGMP hydrolysis.
• This inhibition enhances NO-mediated smooth muscle relaxation.
• Sildenafil improves erectile function in men with erectile dysfunction.

Conclusions:

• Sildenafil citrate is an effective treatment for erectile dysfunction.
• Understanding PDE type 5 inhibition is key to managing erectile dysfunction.
• Sildenafil's mechanism involves enhancing natural erectile pathways.